期刊
BIOMATERIALS
卷 35, 期 22, 页码 5921-5931出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2014.03.073
关键词
Bioactive biomaterial; Mesenchymal stem cell; Lentivirus; Cartilage repair; Osteoarthritis; Immunoengineering
资金
- NIH [AR061042, AR50245, AR48852, AG15768, AR48182, AG46927, OD008586, P01 CA47741]
- NSF CAREER Award [CBET-1151035]
- Collaborative Research Center, AO Foundation, Davos, Switzerland
- Arthritis Foundation
- Nancy Taylor Foundation
- NSF GRFP
The pathogenesis of osteoarthritis is mediated in part by inflammatory cytokines including interleukin-1 (IL-1), which promote degradation of articular cartilage and prevent human mesenchymal stem cell (MSC) chondrogenesis. In this study, we combined gene therapy and functional tissue engineering to develop engineered cartilage with immunomodulatory properties that allow chondrogenesis in the presence of pathologic levels of IL-1 by inducing overexpression of IL-1 receptor antagonist (IL-1Ra) in MSCs via scaffold-mediated lentiviral gene delivery. A doxycycline-inducible vector was used to transduce MSCs in monolayer or within 3D woven PCL scaffolds to enable tunable IL-1Ra production. In the presence of IL-1, IL-1Ra-expressing engineered cartilage produced cartilage-specific extracellular matrix, while resisting IL-1-induced upregulation of matrix metalloproteinases and maintaining mechanical properties similar to native articular cartilage. The ability of functional engineered cartilage to deliver tunable anti-inflammatory cytokines to the joint may enhance the long-term success of therapies for cartilage injuries or osteoarthritis. (C) 2014 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据